☆ 4.7 Article

Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2

VACCINES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Medicinal

Formulation and Evaluation of Lipidized Imiquimod as an Effective Adjuvant

Wenzhu Yin et al.

Summary: A novel vaccine adjuvant, IMQ-Chol, was designed and synthesized to release IMQ molecules in aqueous conditions, and its immunological evaluations with FMDV confirmed its ability to stimulate prolonged and strong humoral and cellular immune responses via the TLR7-related MAPK pathway. The proof-of-concept vaccine also demonstrated the effectiveness of IMQ-Chol in preventing and treating FMD in pigs.

ACS INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways

Daniel Mekonnen et al.

Summary: Vaccines with adjuvants play a crucial role in combating the COVID-19 pandemic, offering high efficacy, safety, and a broad spectrum of immune response. Future research will focus on optimizing the pairing of adjuvants and antigens for desired vaccine effects, as well as further exploring and developing new adjuvanted subunit vaccines.

EXPERT REVIEW OF VACCINES (2022)

添加到收藏夹

Review Virology

The global epidemic of SARS-CoV-2 variants and their mutational immune escape

Dandan Tian et al.

Summary: During the COVID-19 pandemic, various variants of SARS-CoV-2 have emerged, showing increased infectivity and immune escape, posing new challenges to epidemic prevention and control.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Delphine Planas et al.

Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.

NATURE (2022)

添加到收藏夹

Article Virology

A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination

Zhidong Hu et al.

Summary: This study investigated the adjuvant effect of AS01 in a COVID-19 vaccine. The results showed that the adjuvanted vaccine induced strong antibody responses, and two doses of the vaccine were as effective as three doses.

VIROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Defining the risk of SARS-CoV-2 variants on immune protection

Marciela M. DeGrace et al.

Summary: The SAVE program is a real-time risk assessment initiative established by the National Institute of Allergy and Infectious Diseases to address the public health threat posed by the emergence of SARS-CoV-2 variants. Its goal is to evaluate the potential impact of these variants on transmission, virulence, and immunity induced through infection or vaccination.

NATURE (2022)

添加到收藏夹

Article Medical Laboratory Technology

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge

Juan Shi et al.

Summary: The RBD-mRNA vaccine induces durable antibodies that neutralize various SARS-CoV-2 variants, providing potential protection. However, there is a slight reduction in neutralizing activity against certain variants. These findings highlight the importance of designing novel vaccines with improved neutralization against current and future variants.

TRANSLATIONAL RESEARCH (2022)

添加到收藏夹

Article Virology

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection

Juan Shi et al.

Summary: This study identified a non-neutralizing epitope on the receptor-binding domain (RBD) of SARS-CoV-2 spike protein and developed a mutant RBD vaccine with enhanced neutralizing activity against multiple variants, including Delta and Omicron strains. The mutant vaccine also improved the protective efficacy of the prototypic RBD vaccine against SARS-CoV-2 infection.

JOURNAL OF VIROLOGY (2022)

添加到收藏夹

Article Immunology

Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern

Juan Shi et al.

Summary: This study evaluated the neutralizing activity and protection provided by a BA1-S subunit vaccine in combination with or as a booster dose after administration of wild-type S protein. The results showed that the vaccine elicited high levels of neutralizing antibodies and provided protection against multiple SARS-CoV-2 variants and related coronaviruses. This provides useful guidance for developing effective vaccines to control the COVID-19 pandemic.

NPJ VACCINES (2022)

添加到收藏夹

Review Virology

Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission

Lok Bahadur Shrestha et al.

Summary: The Omicron variant of SARS-CoV-2 is a major public health concern due to its high infectivity and antibody evasion. It has rapidly become the dominant variant worldwide and has evolved through several variants. The evolution of Omicron is thought to be influenced by zoonotic spillage, infection in immunocompromised individuals, and undiagnosed spread in the community. Current research suggests that Omicron is more infectious than the original Wuhan-Hu-1 and Delta variants, but less severe in terms of its impact on lung tissue. Vaccines have shown reduced effectiveness against Omicron, but booster shots can improve efficacy. Broadly neutralizing monoclonal antibodies have limited effectiveness against Omicron, with some exceptions. New variants, such as BA.4 and BA.5, are emerging and are reported to be more transmissible and resistant to immunity generated by previous variants and monoclonal antibodies.

REVIEWS IN MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern

Gang Wang et al.

Summary: The latest research shows that new vaccine strategies are needed to combat SARS-CoV-2 variants of concern, particularly the Omicron subvariant. A vaccine encoding the spike protein of Omicron BA1 was designed and tested, and it was found that the strategy of administering BA1-S-mRNA followed by two doses of RBD-mRNA can effectively induce neutralizing antibodies against multiple SARS-CoV-2 variants.

ISCIENCE (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates

Yin-Feng Kang et al.

Summary: The RBD-conjugated nanoparticles designed in this study show promising immunization effects in mice, with higher neutralizing activity against the virus and more efficient blocking of RBD-ACE2 binding. These results suggest that the vaccine is a competitive candidate, and the carrier nanoparticles could serve as a universal platform for future vaccine development.

ACS NANO (2021)

添加到收藏夹

Article Immunology

Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice

Juan Shi et al.

Summary: The study constructed RBD-Fc proteins that can bind to specific mutant virus strains and demonstrated in mouse immunization experiments that these proteins can induce high levels of IgG antibodies and cross-neutralizing antibodies. Furthermore, RBD-Fc proteins with multiple amino acid substitutions showed higher antibody titers and neutralizing-antibody titers compared to those with single substitutions.

VACCINES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Prabhu S. Arunachalam et al.

Summary: This study demonstrated the effectiveness of an adjuvanted RBD-NP vaccine in inducing robust and durable neutralizing antibody responses, providing protection against SARS-CoV-2 infection, and cross-neutralizing various variants. Adjuvants such as AS03 and AS37 significantly enhanced the immunogenicity of the vaccine and have the potential to be candidates for COVID-19 vaccines.

NATURE (2021)

添加到收藏夹

Letter Cell Biology

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

Wanbo Tai et al.

CELL RESEARCH (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2

Shibi Muralidar et al.

BIOCHIMIE (2020)

添加到收藏夹

Article Oncology

Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

Carolina Porras et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?

Huseyin Avcilar et al.

MEDICAL HYPOTHESES (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

Tino F. Schwarz et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)

添加到收藏夹

Article Immunology

Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine

Xinyi Wang et al.

VACCINES (2019)

添加到收藏夹

Article Immunology

Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production

Can Li et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Physiology

Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study

Fabrizio Fabrizi et al.

KIDNEY & BLOOD PRESSURE RESEARCH (2015)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

H. Tinto et al.

LANCET (2015)

添加到收藏夹

Article Immunology

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

Samuele Calabro et al.

VACCINE (2013)

添加到收藏夹

Article Immunology

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

Najoua Dendouga et al.

VACCINE (2012)

添加到收藏夹

Review Oncology

Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach

Nathalie Garcon et al.

BIODRUGS (2011)

添加到收藏夹

Review Dermatology

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

MA Stanley

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2002)

添加到收藏夹

Article Immunology

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

H Hemmi et al.

NATURE IMMUNOLOGY (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.